2022
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
Perl A, Larson R, Podoltsev N, Strickland S, Wang E, Atallah E, Schiller G, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon S, Maeda Y, Hosono N, Onozawa M, Kato T, Kim H, Hasabou N, Nuthethi R, Tiu R, Levis M. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transplantation And Cellular Therapy 2022, 29: 265.e1-265.e10. PMID: 36526260, PMCID: PMC10189888, DOI: 10.1016/j.jtct.2022.12.006.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationAcute myelogenous leukemiaPost-transplantation maintenance therapyLower relapse rateAdverse eventsADMIRAL trialMaintenance therapyPost-transplantation survivalGilteritinib armRelapse rateSalvage chemotherapyMyelogenous leukemiaRefractory acute myelogenous leukemiaTreatment-emergent adverse eventsFLT3 internal tandem duplication (ITD) mutationsCommon adverse eventsComposite complete remissionGlobal phase 3Incidence of gradePost-transplantation complicationsTransplantation-eligible patientsAlanine aminotransferase levelsHigher remission ratesOverall survival rateSurvival of patientsRates of idiopathic childhood nephrotic syndrome relapse are lower during the COVID-19 pandemic
Crane C, Bakhoum C, Ingulli E. Rates of idiopathic childhood nephrotic syndrome relapse are lower during the COVID-19 pandemic. Pediatric Nephrology 2022, 37: 2679-2685. PMID: 35211788, PMCID: PMC8869345, DOI: 10.1007/s00467-022-05483-8.Peer-Reviewed Original ResearchConceptsSteroid-sensitive nephrotic syndromeRate of relapseNephrotic syndromeTransmission of infectionNS relapseGraphical abstractA higher resolution versionSingle-center retrospective chart reviewNephrotic syndrome relapseSteroid-sensitive NSRetrospective chart reviewLower relapse rateRate of hospitalizationInfection prevention measuresResultsOne hundred twentyCOVID-19 pandemicPre-pandemic periodChart reviewRelapse rateInfection preventionHundred twentyRelapseStudy periodSocial distancing periodConclusionsOur resultsDecreased rate
2020
The Role of Medical Therapy for Menigniomas
Roque A, Omuro A. The Role of Medical Therapy for Menigniomas. 2020, 201-215. DOI: 10.1007/978-3-030-59558-6_13.Peer-Reviewed Original ResearchSystemic therapyProspective single-arm studyNatural historyCurrent NCCN guidelinesLower relapse rateMajority of patientsSingle-arm studySmall patient populationVaried outcome measuresNCCN guidelinesRefractory meningiomasRepeat surgerySurgical resectionSystemic treatmentLocal therapyMedical therapyProlong survivalRelapse rateSurgical optionsArm studyPatient populationSomatostatin analoguesGrade IGrade IIAntiangiogenic agentsContinuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment‐resistant major depressive disorder: A VAST‐D report
Zisook S, Johnson G, Hicks P, Chen P, Beresford T, Michalets J, Rao S, Thase M, Wilcox J, Sevilimedu V, Mohamed S. Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment‐resistant major depressive disorder: A VAST‐D report. Depression And Anxiety 2020, 38: 185-195. PMID: 33225492, DOI: 10.1002/da.23114.Peer-Reviewed Original ResearchConceptsDepressive symptom severityContinuation treatmentBupropion SRTreatment outcomesTreatment-resistant major depressive disorderSymptom severitySignificant differential treatment effectsContinuation treatment phaseAcute-phase treatmentAbnormal laboratory valuesLower relapse rateMajor depressive disorderQuality of lifeLess anxietyDifferential treatment effectsMore somnolenceDry mouthRelapse rateExtrapyramidal effectsFull remissionWeek 12Continuation phaseTreatment attemptsDepressive disorderLaboratory values
1994
Adjuvant systemic chemotherapy and hormonal therapy. Effect on local recurrence in the conservatively treated breast cancer patient
Haffty B, Wilmarth L, Wilson L, Fischer D, Beinfield M, McKhann C. Adjuvant systemic chemotherapy and hormonal therapy. Effect on local recurrence in the conservatively treated breast cancer patient. Cancer 1994, 73: 2543-2548. PMID: 8174051, DOI: 10.1002/1097-0142(19940515)73:10<2543::aid-cncr2820731015>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsAdjuvant systemic therapyAdjuvant systemic chemotherapyLower relapse rateMajority of patientsSystemic therapySystemic chemotherapyRadiation therapyBreast relapseHormonal therapyLymph nodesRelapse rateSignificant independent prognostic factorAdjuvant hormonal therapyNegative lymph nodesCox regression analysisIndependent prognostic factorBreast cancer patientsAxillary dissectionLocal relapseLocal recurrencePatient agePrognostic factorsCancer patientsRetrospective analysisIntact breast
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply